Stefano Gustincich is Director of the “Central RNA Lab" of the Italian Institute of Technology (IIT), Genoa, Italy and Director of “Centro per la Medicina Personalizzata Preventiva e Predittiva – CMP3VdA” in Aosta (IIT), Italy.
He was Full Professor in Applied Biology at the International School of Advanced Advanced Studies (SISSA), Trieste, Italy (2015-2022).
After obtaining a PhD in Molecular Genetics & Biotechnology from SISSA, he was awarded a "long-term EMBO fellowship" at the Department of Neurobiology of Harvard Medical School, Boston (USA) where in 1998 he became "Instructor in Neurobiology".
In 2003 he won the "career development award" of the Giovanni Armenise-Harvard Foundation and in 2011 the National Award for Innovation in Biotechnology.
His lab studies the role of non-coding DNA in brain function and neurodegenerative diseases. He recently discovered the SINEUPs, a new functional class of antisense long noncoding RNAs able to increase translation of their sense gene.
Since the beginning of his scientific career, he published 164 peer-reviewed research articles and reviews with an average IF of 10.6, a h Index of 56 and more than 22.000 citations. He is the inventor in 12 patents.
He is the co-founder of TranSINE Therapeutics, an IIT start-up based in Cambridge, UK.
He is the leader of Spoke 3 "Neurodegenerative diseases" of the "National Center 3 in Gene Therapy and Drugs Based On RNA Technology”